Feature | January 23, 2014

Nanotherapy Advancement May Help Reduce Recurrent Heart Attacks and Stroke

HDL nanoparticle delivers statin medication to inflamed blood vessels, prevents repeat heart attacks, stroke

January 23, 2014 — Up to 30 percent of heart attack patients suffer an additional heart attack because of limited ability to control inflammation inside heart arteries that leads to clots rupturing and myocardial infarction or stroke.
 
An international research team, led by Icahn School of Medicine at Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a statin drug. In mouse studies, they show HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels.
 
HDL nanotherapy could potentially avert repeat heart attacks and may also reduce recurrent strokes caused by clots in brain arteries. 
 
The nanoparticles resemble HDL cholesterol particles and bind to the same receptors as natural HDL in order to deliver the statin drug. Oral statin medications work primarily in the liver to reduce levels of unhealthy lipids circulating in the blood. Statins also exert a very weak dampening effect on some inflammatory cells, foremost macrophages that hide in plaque in arterial walls. Researchers sought to bolster this anti-inflammatory function in their HDL nanotherapy design.
 
 “Levels of inflammation spike after a heart attack, which is why up to 30 percent of heart attack patients may suffer another heart attack, some while in hospital or just after discharge,” said co-author Zahi Fayad, Ph.D., professor of radiology and director of the Translational and Molecular Imaging Institute at Icahn.
 
According to Mount Sinai researchers, the best way to use their HDL nanotherapy is by injection after the clot that produces a heart attack or stroke has been treated. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response.
“Our study also confirms that the HDL nanoparticle is not seen as a foreign invader by the body’s immune system and that it has an inherent and natural affinity to target plaque macrophages,” said first author Jun Tang, Ph.D, M.S.
 
The team intends to conduct a clinical trial to test the HDL nanotherapy on humans. 
 
For more information: www.mountsinai.org

Related Content

Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Spectranetics Bridge Occlusion Balloon in the SVC

An illustration of how the Bridge balloon can seal the SVC after an accidental tear from lead extration.

Feature | EP Lab| May 17, 2017 | Dave Fornell
May 17, 2017 — A new intravenous occlusion balloon designed to seal any accidental tears in the superior vena cava (S
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Early Treatment for NSTEMI Patients Shows Greater Rate of Survival
News | Cath Lab| May 16, 2017
An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within...
micra leadless pacemaker
Feature | Pacemakers| May 16, 2017
May 16, 2017 - The preliminary results for the Medtronic Micra Transcatheter Pacing System (TPS) Post-Approval Regist
Medtronic Reveal Linq implantable cardiac monitor

The Medtronic Reveal Linq implantable cardiac monitor is the smallest implantable monitor on the market. It is used as a long-term Holter monitor for 24-hour a day, 365-day a year patient monitoring. The device uses wireless connectivity to download the patient data with a patient bedside base unit to send the information over the internet so it is accessible by physicians.

Feature | Atrial Fibrillation| May 16, 2017
May 16, 2017 - The study using small, subcutaneous implantable cardiac monitors for long-term, 24-hour a day monitori
NewPace string subcutaneous ICD system

The NewPace string subcutaneous ICD system.

News | May 16, 2017
May 16, 2017 – A new study examines the effectiveness of the implantable subcutaneous string defibrillator (ISSDTM),
Overlay Init